Windtree Therapeutics, Inc. EPS Growth (basic)

EPS Growth (basic) of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including EPS Growth (basic) growth rates and interactive chart. Year over year growth in basic earnings per share.


Highlights and Quick Summary

  • EPS Growth (basic) for the quarter ending June 29, 2020 was -4.98% (a -124.89% decrease compared to previous quarter)
  • Year-over-year quarterly EPS Growth (basic) decreased by -106.32%
  • Annual EPS Growth (basic) for 2019 was 89.15% (a 31.22% increase from previous year)
  • Annual EPS Growth (basic) for 2018 was 67.94% (a -8.85% decrease from previous year)
  • Annual EPS Growth (basic) for 2017 was 74.54% (a 83.6% increase from previous year)
  • Twelve month EPS Growth (basic) ending June 29, 2020 was 82.91% (a -2.54% decrease compared to previous quarter)
  • Twelve month trailing EPS Growth (basic) decreased by -212.22% year-over-year
Trailing EPS Growth (basic) for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
82.91% 85.07% 87.21% -73.88%
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EPS Growth (basic) of Windtree Therapeutics, Inc.

Most recent EPS Growth (basic)of WINT including historical data for past 10 years.

Interactive Chart of EPS Growth (basic) of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. EPS Growth (basic) for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -4.98% 20.01%
2019 93.52% 78.84% 75.31% 85.71% 89.15%
2018 -414.56% 92.46% 94.67% 94.89% 67.94%
2017 106.69% 31.0% 41.08% 19.41% 74.54%
2016 38.89% 64.3% 29.15% 13.3% 40.6%
2015 25.03% -53.85% -8.33% 0.0% -9.57%
2014 25.0% 40.91% 33.33% 51.72% 36.59%
2013 0.0% 29.03% -5.88% 21.62% 13.68%
2012 11.11% -55.0% 50.0% -76.19% -2.15%
2011 57.14% -566.66% 43.3% 71.99% 43.64%

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.